Clinical, virologic and immunologic features of a mild case of SARS-CoV-2 reinfection.
COVID-19
Immunity
Reinfection
SARS-CoV-2
Sequencing
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420
Informations de publication
Date de publication:
20 Feb 2021
20 Feb 2021
Historique:
received:
06
01
2021
revised:
08
02
2021
accepted:
09
02
2021
pubmed:
23
2
2021
medline:
23
2
2021
entrez:
22
2
2021
Statut:
aheadofprint
Résumé
To report a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection 6 months after the first infection in a young healthy female physician. Both episodes led to mild coronavirus disease 2019 (COVID-19). SARS-CoV-2 infections were detected by real-time reverse transcriptase PCR (RT-PCR) on nasopharyngeal specimens. Reinfection was confirmed by whole-genome sequencing. Kinetics of total anti-S receptor binding domain immunoglobulins (Ig anti-S RBD), anti-nucleoprotein (anti-N) and neutralizing antibodies were determined in serial serum samples retrieved during both infection episodes. Memory B-cell responses were assessed at day 12 after reinfection. Whole-genome sequencing identified two different SARS-CoV-2 genomes both belonging to clade 20A, with only one nonsynonymous mutation in the spike protein and clustered with viruses circulating in Geneva (Switzerland) at the time of each of the corresponding episodes. Seroconversion was documented with low levels of total Ig anti-S RBD and anti-N antibodies at 1 month after the first infection, whereas neutralizing antibodies quickly declined after the first episode and then were boosted by the reinfection, with high titres detectable 4 days after symptom onset. A strong memory B-cell response was detected at day 12 after onset of symptoms during reinfection, indicating that the first episode elicited cellular memory responses. Rapid decline of neutralizing antibodies may put medical personnel at risk of reinfection, as shown in this case. However, reinfection leads to a significant boosting of previous immune responses. Larger cohorts of reinfected subjects with detailed descriptions of their immune responses are needed to define correlates of protection and their duration after infection.
Identifiants
pubmed: 33618012
pii: S1198-743X(21)00085-9
doi: 10.1016/j.cmi.2021.02.010
pmc: PMC7896115
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Références
Lancet Infect Dis. 2021 Jan;21(1):52-58
pubmed: 33058797
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Clin Infect Dis. 2021 Nov 2;73(9):e2841-e2842
pubmed: 33043962
Clin Microbiol Infect. 2021 Mar;27(3):315-318
pubmed: 33285276
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
Clin Infect Dis. 2021 Nov 2;73(9):e2823-e2825
pubmed: 32964927
mSphere. 2020 Nov 11;5(6):
pubmed: 33177214
Clin Infect Dis. 2021 Nov 2;73(9):e2827-e2828
pubmed: 32949240
Clin Infect Dis. 2021 Jul 1;73(1):148-150
pubmed: 32761228
Eur J Immunol. 2020 Dec;50(12):2025-2040
pubmed: 33084029
Clin Infect Dis. 2021 May 18;72(10):e659-e662
pubmed: 32966566
Nature. 2021 Jul;595(7869):707-712
pubmed: 34098568
Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4
pubmed: 33535027
Lancet Infect Dis. 2021 Jun;21(6):e142
pubmed: 33242475
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951
pubmed: 32840608